Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (aPDL1) in Combination With Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma (GBM)
Phase of Trial: Phase I/II
Latest Information Update: 12 Jul 2018
At a glance
- Drugs Atezolizumab (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions; Therapeutic Use
- 29 Jun 2018 Planned End Date changed from 1 Jun 2021 to 23 Nov 2020.
- 29 Jun 2018 Planned primary completion date changed from 1 Jun 2020 to 23 Nov 2020.
- 26 Mar 2018 Planned End Date changed from 1 Jun 2020 to 1 Jun 2021.